Hypoxia-inducible factor signaling in vascular calcification in chronic kidney disease patients

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Molecular Biology

Background:

• Chronic kidney disease (CKD) affects 15% of adults in high-income nations, increasing cardiovascular event risk.
• Vascular calcification is a major comorbidity in CKD, though its pathophysiology is not fully understood.
• Hypoxia-inducible factor (HIF) signaling is recognized as a key player in CKD-related inflammation, fibrosis, and vascular calcification.

Purpose of the Study:

• To review the role of HIF signaling in the development of vascular calcification in CKD.
• To explore emerging therapeutic strategies targeting HIF signaling for vascular calcification in CKD.

Main Methods:

• Literature review focusing on the role of HIF signaling in CKD pathophysiology.
• Analysis of factors influencing HIF signaling, including iron deficiency, mineral levels, FGF-23, and Klotho.
• Discussion of potential therapeutic interventions such as HIF stabilizers and SGLT-2 inhibitors.

Main Results:

• HIF signaling influences multiple pathways involved in vascular calcification, including inflammation, angiogenesis, and cellular processes.
• Factors like iron deficiency anemia, serum phosphorus, calcium, FGF-23, and Klotho modulate HIF activity in CKD.
• HIF stabilizers and SGLT-2 inhibitors represent promising therapeutic avenues for managing vascular calcification in CKD patients.

Conclusions:

• HIF signaling is a critical mediator in the pathophysiology of vascular calcification in CKD.
• Targeting HIF signaling pathways offers potential for novel therapeutic strategies to mitigate cardiovascular risk in CKD patients.